CURRICULUM VITAE - Isped

Rodolphe THIEBAUT
CURRICULUM VITAE
Date of birth: January 3 rd , 1973 in Neuilly sur Seine (FRANCE)
Professional address
ISPED - INSERM U897
Université Bordeaux 2 - Case 11
146 Rue Leo Saignat 33076 Bordeaux Cedex. France
Tel: (33) 5-57-57-45-21
Fax: (33) 5-56-24-00-81
E-mail: rodolphe.thiebaut@isped.u-bordeaux2.fr
Web: http://www.isped.u-bordeaux2.fr/ISPED/ANNUAIRE/FR-R_THIEBAUT.htm
POSITION TITLE
Research Director (DR2) at the French Institute for Health and Medical Research (INSERM),
Research Centre U897 “Epidemiology and Biostatistics” (Tenure Track since 2002)
Deputy Director of the Research Centre U897 (Since 2008), Deputy Director of the Bordeaux
School of Public Health (ISPED) for the Research (Since 2009)
Fellow at the Clinical Research Unit (USMR), Bordeaux University Hospital (since 2003)
Honorary Research Fellow at the Infectious Diseases and Microbiology unit at the Institute of
Child Health, London (Since 2007)
EDUCATION
Institution and location
Degree Year Field of study
Bordeaux 2 University M.D. 2000 Public Health
Bordeaux 2 University Ph.D. 2002 Biostatistics
Bordeaux 2 University Ability for steering
PhD students (HDR)
2004 -
MAIN RESEARCH ACTIVITIES
� 2003-now: Dynamical modelling in immunology and infectious diseases & Immuno-
Epidemiology
� 1999-now: Development and application of methods for the statistical analysis of repeated
markers
� 1998-now: Assessment of the effectiveness and side effects of antiretroviral therapy in HIV
infected patients in randomized clinical trials and observational cohort studies
� 2002-2005: Evaluation of the prevention of the congenital toxoplasmosis (consensus initiative
and meta-analysis)
SUPERVISOR FOR PHD
� 2006-2010: Linda Wittkop, co-supervisor with Daniel Commenges, PhD in Biostatistics
« Statistical analysis of the impact of HIV-1 genotypic mutations on virological response to
antiretroviral therapy. Grant from the NEAT network & Sidaction
06/09/07 1/19

� 2006-2009: Julia Drylewicz, PhD in Biostatistics « Dynamical Models of HIV using
observational cohort studies”, Bordeaux 2 University. European grant from the CASCADE
collaboration
� 2003-2006: Jérémie Guedj, PhD in Biostatistics « Parameter Estimation in Dynamical Models
of HIV”, Bordeaux 2 University. Grant from French National Agency for AIDS Research.
TEACHING ACTIVITIES
� Director of the Master in Science 2 “Research in Epidemiology” (Since 2007)
� Analysis of longitudinal data for Master Students (Since 2000, 30 hours/year)
� Meta-analysis for Master Students (Since 2001, 10 hours/year)
SCIENTIFIC BOARDS AND COMMITTEES MEMBER
� 2009-now : Member of the committee on methodology and statistics of the european network
EuroCoord
� 2009-now : Deputy director of the Bordeaux School of Public Health (IPSED) for research
activities
� 2009-now : Member of the Scientific committee of the Doctoral School « Sciences de la vie et
de la Santé »
� 2008-now: Member of the workpackage 4 (Methodology) of The European AIDS Treatment
Network, (NEAT, http://ec.europa.eu/research/health/poverty-diseases/projects/131_en.htm)
� 2008-now: Member of the scientific advisory board of the PROMISE-PEP trial (ANRS 12174)
� 2008-now: Member of the scientific committee (CSS) 3 « Clinical research in HIV infection »
of the National French Agency for AIDS research
� 2007-now: Honorary Research Fellow at the Infectious Diseases and Microbiology unit at the
Institute of Child Health, London
� 2007-now: Member of the scientific committee of the ANRS PRIMOCI Cohort
� 2007-now: Expert for the scientific and medical committee of the SIDACTION Charity
� 2006-now: Methodologist for the West Africa Database on Antiretroviral therapy (WADA,
http://www.iedea-westafrica.com/, PI François Dabis)
� 2006- now: Member at the expert committee « Immunology and cancer », ANRS AC n°5
Clinical trials (Pr JM Molina)
� 2005: Jury member of the first European Consensus Conference on the treatment of chronic
hepatitis B and C in HIV co-infected patients
� 2004-now: Member of the Scientific Advisory Committee of the French ANRS COPANA
Cohort
� 2000-2007: Aquitaine cohort coordinator for the DAD collaboration (Data collection on
Adverse events of anti-HIV Drugs, www.cphiv.dk/dad)
� 2002-2005: Member of the Scientific Secretariat and chair of panel 2 for the European
Consensus initiative on the state-of-the-science for the Prevention of Congenital Toxoplasmosis
(http://eurotoxo.isped.u-bordeaux2.fr)
RESEARCH SUPPORT
� 2008-2010: Principal investigator and coordinator of RHOMEO project « Applied statistical
and mathematical modelling of peripheral T-Lymphocytes homeostasis”, ANR-BBSRC SYSTEM
BIOLOGY call for proposal, 208 K€
� 2006-2007: Grants from National French agency for AIDS research (ANRS) for sub-study on
dynamical modelling of HIV-immune system interaction in the ANRS ILIADE randomised clinical
trial (PI: Pr Yves Levy). Role: Principal investigator of the sub-study. 88 K€
06/09/07 2/19

� 2001-2006: Grants from European Commission (FP5, Contract No. QLG4-CT-2002-30262) for
EUROTOXO: A European Consensus initiative on the state-of-the-science for the prevention of
congenital toxoplasmosis. Role: co-investigator.
REVIEWER
Reviewer for the following journals:
- Biostatistics & methodology: American Journal of Epidemiology, Biometrics, Biostatistics,
Computer Methods and Programs in Biomedicine, Contemporary Clinical Trials, Statistics
in Medicine, Statistical Modelling
- Medicine : AIDS, Annals of Internal Medicine, Antiviral Therapy, Blood, BMC Infectious
Diseases, Clinical infectious disease, Drug Safety, European Journal of Clinical
Microbiology & Infectious Diseases, HIV Clinical Trials, HIV Medicine, The Journal of
Infectious Diseases, The Open Infectious Diseases Journal
06/09/07 3/19

PUBLICATIONS
� Published papers:
1998
98-1 Thiébaut R, Birba E, Ouédraogo M. A, Malvy D. Prévalence du goitre endémique dans le
secteur sanitaire de Zitenga (Burkina Faso). Cahiers Santé 1998;8:269-74.
98-2 Thiébaut R, Thiessard F, Dequae Merchadou L, Marimoutou C, Dabis F and the GECSA study
group. Antiretroviral combination therapy and HIV infection. Long term follow up of patients under
triple therapy is necessary [Letter]. British medical journal 1998;317:887-8.
1999
99-1 Thiébaut R, Martin C, Grabot D, Verdun-Esquer C, Gabinski P, Tignol J. Prevalence and risk
factors of mood, anxiety disorders, and alcohol dependence in a French ancillary staff population.
European Journal of Psychiatry 1999;17:1-7.
2000
00-1 Thiébaut R, Daucourt V, Mercié P, Ekouévi DK, Malvy D, Morlat P, Dupon M, Neau D,
Farbos S, Marimoutou C, Dabis F and the GECSA. Lipodystrophy, metabolism disorders and
HIV infection. Aquitaine Cohort, 1999. Clinical Infectious Diseases 2000 ;31:1482-7.
00-2 Thiébaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercié P, Daucourt V and the GECSA.
Serum triglycerides, HIV infection and highly active antiretroviral therapy. Aquitaine Cohort,
France, 1996-1998. Journal of acquired immune deficiency syndromes 2000;23:261-5.
00-3 Thiébaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercié P, Dabis F, Chêne G and the
GECSA. Clinical progression of HIV-1 infection according to the viral response during the first
year of antiretroviral treatment. AIDS 2000;14:971-8.
00-4 Thiébaut R, Malvy D, Marimoutou C, Dabis F and the GECSA. Anthropometric indices as
predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. European Journal of
Epidemiology 2000;16:633-9.
06/09/07 4/19

00-5 Jacqmin-Gadda H, Thiébaut R, Chêne G, Commenges D. Analysis of left-censored
longitudinal data with application to viral load in HIV. Biostatistics, 2000;1:355-68.
00-6 Receveur MC, Blanc B, Malvy D, Thiébaut R, Le Bras M. Le paludisme au Vietnam : quelle
connaissance du risque pour le voyageur en 2000. (courte note n°2106). Bulletin de la Société de
Pathologie Exotique 2000;93:119-20.
00-7 Malvy D, Djossou F, Thiébaut R, Le Bras M. Plasmodies – Malaria. Formes cliniques,
diagnostic. Encyclopédie Médico Chirurgicale, Maladies Infectieuses, Elsevier Ed, Paris, 8-507-A-
20, 2000, 16p.
00-8 Receveur MC, Thiébaut R, Vedy S, Malvy D, Le Bras M. Yellow fever vaccination and HIV
infected patients : cases report [Letter]. Clinical Infectious Diseases 2000;9:e7-e8.
00-9 Mercié P, Tchamgoué S, Thiébaut R, Viallard JF, Faure I, Daucourt V, Marimoutou C, Dabis
F, Rispal P, Darmon YM, Leng B, Pellegrin JL. Atherogen lipid profile in HIV-1 infected patients
with lipodystrophy syndrome. European Journal of Internal Medicine 2000;11: 257-63.
2001
01-1 Thiébaut R, Dequae-Merchadou L, Ekouevi D.K , Mercié P, Malvy D, Neau D, Dabis F and
the Groupe d’Epidémiologie du SIDA en Aquitaine (GECSA). Incidence and risk factors of severe
hypertriglyceridemia in the era of HAART. Aquitaine Cohort, France, 1996-1999. HIV Medicine,
2001;2:84-8.
01-2 Malvy D, Thiébaut R, Marimoutou C, Dabis F and the GECSA. Weight loss and body mass
index as predictors of HIV disease progression to AIDS in adults. Aquitaine Cohort, France, 1985-
1997. Journal of the American College of Nutrition, 2001;20:609-15.
01-3 Mercié P, Viallard JF, Thiébaut R, Faure I, Rispal P, Leng B, Pellegrin JL. Efavirenz-
Associated Breast Hypertrophy in HIV-Infected Patients [letter]. AIDS, 2001;15:126-8.
01-4 Beylot-Barry M, Sibaud V, Thiébaut R, Vergier B, Ferrer J, Beylot C, Delaunay M, Chêne G,
Dubus P, Merlio JP. PCR detection of an identical T-cell clone in skin and peripheral blood
06/09/07 5/19

lymphocytes is an independant prognostic factor in primary cutaneous T-cell lymphomas. Journal
of Investigative Dermatology, 2001;117:920-6.
01-5 Iskandar H, Guillaume E, Dixmérias F, Binje B, Rakotondriamihary S, Thiébaut R, Maurette
P. Enhancement of sensory blockade by clonidine selectively added to mepivacaine after
midhumeral block. Anesthesia and analgesia, 2001;93:771-5.
2002
02-1 Thiébaut R, Jacqmin-Gadda H, Chêne G, Leport C, Commenges D. Bivariate linear mixed
models using SAS proc MIXED. Computer Methods and Programs in Biomedicine, 2002;69:249-
56.
02-2 Le Moing V, Thiébaut R, Chêne G, Leport C, Moatti JP, Michelet C, Fleury H, Herson
S, Raffi F and the APROCO Study Group. Predictors of long-term increase of CD4+ cell
counts in human immunodeficiency virus-infected patients initiating a protease inhibitor-
containing regimen. Journal of Infectious Disease, 2002;185:471-80.
02-3 Mercié P, Thiébaut R, Lavignolle V, Pellegrin J.L, Yvorra-Vives M.C, Morlat P, Ragnaud
J.M, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F, and The GECSA.
Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media
thickness measurement. Annals of Medicine, 2002;34:55-63.
02-4 Bonnet F, Lawson-Ayayi S, Thiébaut R, Ramanampamonjy R, Lacoste D, Bernard N, Malvy
D, Bonarek M, Djossou F, Beylot J, Dabis F, Morlat P. A Cohort Study of Nevirapine Tolerance in
Clinical Practice: French Aquitaine Cohort, 1997-1999. Clinical Infectious Diseases. 2002;35:1231-
7.
02-5 Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, Beral V, Coutinho R, Del
Amo J, Gill N, Lee C, Meyer L, Tyrer F, Dabis F, Thiébaut R, Lawson-Ayayi S, Boufassa F,
Hamouda O, Fischer K, Pezzotti P, Rezza G, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou
O, Brettle R, del Romero J, Prins M, van Benthem B, Kirk O, Pederson C, Hernandez Aguado I,
Perez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Lee C, Johnson AM, Phillips AN,
Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Ashton L, Vizzard J, Muga
R, Day NE, De Angelis D; CASCADE Collaboration. Changes over calendar time in the risk of
06/09/07 6/19

specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
International Journal of Epidemiology 2002;31:951-8.
2003
03-01 Thiébaut R, Jacqmin-Gadda H, Leport C, Katlama C, Costagliola D, Le Moing V, Morlat P,
Chêne G and the APROCO study group. Joint longitudinal modeling of virologic and immunologic
response to highly active antiretroviral therapy in HIV-infected patients. APROCO Cohort 1997-
2000. Journal Biopharmaceutical Statistics, 2003; 13:271-82.
03-02 Thiébaut R, Jacqmin-Gadda H, Chêne G, Morlat P, Mercié P, Ramaroson H, Dabis F and the
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Time updated CD4+ cell count
and HIV RNA as prognostic factors in HIV-1 infected patients naive of antiretrovirals and newly
treated with an highly active antiretroviral therapy. Aquitaine Cohort, 1996-2000. Journal of
Acquired Immune Deficiency Syndrome, 2003; 33:380-6.
03-03 Thiébaut R, Jacqmin-Gadda H, Journot V, Ferchal F, Rancinan C, Molina JM, Chêne G and
the ALBI Study Group. Analysis of undetectable HIV RNA using survival analysis: results must be
interpreted carefully. HIV Clinical Trials, 2003; 4:417-20.
03-04 Thiébaut R, Savès M, Mercié P, Cipriano C, Chêne G, Dabis F. Epidémiologie du risque
vasculaire d'origine athéroscléreuse chez les patients infectés par le VIH-1. Presse Médicale, 2003;
32:1419-26.
03-05 Friis-Møller N, Sabin CA, Weber R, D'Arminio Monforte A, El-Sadr W, Reiss P,
Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law M, Kirk O, Weller I, Phillips AN
and Lundgren JD. Antiretroviral combination treatment and risk of myocardial infarction.
Results from the D:A:D Study. The New England Journal of Medicine, 2003; 21:1993-2003.
03-06 Law M, Friis-Moller N, Weber R, Reiss P, Thiébaut R, Kirk O, D'Arminio Monforte A,
Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD; For the DAD Study
Group. Modelling the 3-year risk of myocardial infarction among participants in the Data
Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Medicine 2003;4:1-10.
06/09/07 7/19

03-07 Friis-Moller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C,
Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD
study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral
therapy. Results from the DAD study. AIDS, 2003; 17:1179-93.
03-08 Savès M, Thiébaut R, Mercié P, Chêne G. Facteurs de risque vasculaire des lipodystrophies
acquises lors du traitement de l’infection par le VIH. Médecine Clinique Endocrinologie & Diabète,
2003; 74-7.
03-09 Sibaud V, Beylot-Barry M, Thiébaut R, Parrens M, Vergier B, Delaunay M, Beylot C, Chêne
G, De Mascarel A, Dubus P, Merlio JP.Utility of bone-marrow histopathological and molecular
analyses in primary cutaneous T-cell lymphomas. American Journal of Clinical Pathology,
2003;119:414-23.
03-10 Lefevre M, Vergier B, Balme B, Thiébaut R, Delaunay M, Thomas L, Beylot-Barry M,
Machet L, De Muret A, Bioulac-Sage P, Bailly C.Relevance of vertical growth pattern in thin level
II cutaneous superficial spreading melanomas. The American Journal of Surgical Pathology,
2003;27:717-24.
03-11 Thiébaut R, Gilbert RE, Gras L, Chêne G. Effect of timing and type of prenatal treatment on
congenital toxoplasmosis. The Cochrane Library, Issue 1, 2003. Oxford: Update Software (première
parution).
2004
04-1 Thiébaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated
measures. Computer Methods and Programs in Biomedicine, 2004; 74:255-60.
04-2 Bonnet F, Balestre E, Thiébaut R, Mercié P, Dupon M, Morlat P, Dabis F for the Groupe
d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Fibrates or statins and lipid plasma
levels in 245 HAART-treated patients. Aquitaine Cohort, France, 1999-2001. HIV Medicine, 2004;
5:133-9.
06/09/07 8/19

04-3 De LaRoche M, Thiébaut R, Dauman R. Behavioral audiometry: protocols for measuring
hearing thresholds in babies aged 4—18 months. International Journal of Pediatric
Otorhinolaryngology, 2004; 68:1233-43.
04-4 Thiébaut R, Jacqmin-Gadda H. Modélisation longitudinale de données incomplètes : exemple
de la charge virale plasmatique du VIH. Journal de la Société Française de Statistiques, 2004; 145:
33-47.
04-5 Jacqmin-Gadda H, Thiébaut R. Modèles de sélection pour données longitudinales gaussiennes
: Application à l’étude du vieillissement cognitif. Journal de la Société Française de Statistiques,
2004; 145:19-32.
04-6 Jacqmin-Gadda H, Thiébaut R, Dartigues J.F. Modélisation conjointe de données
longitudinales quantitatives et de délais censurés. Revue d'Epidémiologie et de Santé Publique,
2004; 52 :502-510.
04-7 Phillips A., Ledergerber B, Lundgren J, Hogg B, D’Armanio Monforte A, Castelli F, Walker
S, Stasweski S, Thiébaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, James I,
Fisher M, Mussini C, Klein M, Costagliola D. Pre- and within-HAART nucleoside analogue use
and viral load rebound on HAART. The Journal of Infectious Diseases, 2004; 190:675-7.
2005
05-1 Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D and the CASCADE
Collaboration. Bivariate longitudinal study of CD4+ cell count and HIV RNA handling
informative drop-out and left-censoring of HIV RNA values. Statistics in Medicine, 2005,
24:65-82.
05-2 Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P.
Immunological markers evolution after long term supervised treatment interruption in chronically
HIV-1 infected patients with CD4 count above 400 cells/mm 3 . AIDS, 2005, 19:53-61.
05-3 Thiébaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, Dupon M,
Dabis F, Mercié P; Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Change in
06/09/07 9/19

atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS,
2005, 19:729-31.
05-4 Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon
R, Morlat P; for the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly
active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Medicine, 2005, 6:198-
205.
05-5 Alioum A, Commenges D, Thiébaut R, Dabis F. A multi-state approach for estimating HIV
incidence using data from a prevalent cohort study. JRSS C Applied Statistics, 2005, 54:739-752.
05-6 Manuel O, Thiébaut R, Darioli R, Tarr PE. Treatment of dyslipidemia in HIV-infected
persons. Expert Opinion on Pharmacotherapy, 2005, 6:1619-45.
05-7 Pellegrin I, Thiébaut R, Blanco P, Viallard JF, Schrive MH, Merel P, Chêne G, Fleury H,
Moreau JF, Pellegrin JL. Can highly active antiretroviral therapy be interrupted in patients with
sustained moderate HIV- RNA and >400 cd4+ cells/µl? Impact on virological parameters.
Journal of Medical Virology, 2005, 77:164-172.
05-8 Thiébaut R, Leroy V, Alioum A, Binquet C, Poizat G, Salmi LR, Gras L, Salamon R, Gilbert
R, Chêne G. Biases in observational studies of the effect of prenatal treatment for congenital
toxoplasmosis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005,
124:3-9.
05-9 Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL,Yvorra-Vives MC, Cipriano C,
Neau D, Morlat P, Ragnaud JM, Dupon M, Malvy D, Lawson-Ayayi S, Roudaut R, Dabis F on
behalf of the GECSA. Carotid Intima-Media Thickness Increases Over Time in HIV-1 Infected
Patients. HIV Medicine, 2005, 6:380-387.
05-10 Paillard D, Dubois V, Thiébaut R, Nathier F, Hoogland E, Caumette P, Quentin C.
Occurrence of Listeria Spp. in effluents of french urban waste water treatment plants. Applied and
Environmental Microbiology, 2005, 71:7562-7566.
06/09/07 10/19

05-11 Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, Reiss P, D’Arminio Monforte A,
Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G, Law MG, Dabis F, Sabin CA, Lundgren JD and
the “Data Collection of Adverse events of anti-HIV Drugs” (D:A:D) study group. Predictors of
hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005,
10:811-823.
05-12 Taylor JMG, Wang Y, Thiébaut R. Counterfactual links to the proportion of treatment effect
explained by a surrogate marker. Biometrics, 2005, 61:1102-1111.
05-13 Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiébaut R,
Weiland O, Yazdanpanah Y, Zeuzem S; ECC Jury. Short statement of the first European
Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected
patients. Journal of Hepatology, 2005, 42:615-24.
2006
06-01 Thiébaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, Porter K, Dabis F,
Chêne G and CASCADE Collaboration. Determinants of response to first HAART regimen in
antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Medicine, 2006,
7:1-9.
06-02 Bonnet F, Balestre E, Thiébaut R, Morlat P, Pellegrin JL, Neau D, Dabis F, for the Groupe
d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Factors associated with the occurrence
of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy:
Aquitaine Cohort, France. Clinical Infectious Diseases, 2006, 42:411-417.
06-03 Balestre E, Dupon M, Capdepont S, Thiébaut R, Boucher S, Fleury H, Dabis F, Masquelier
B; the GECSA. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase
inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. Journal of
Clinical Virology, 2006, 36:95-99.
06-04 Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, Thiébaut
R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN and Lundgren JD for
the D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in
06/09/07 11/19

HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 2006,
7:218-230.
06-05 Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Commenges D, Dabis F, Moreau JF,
Pellegrin JL, Thiébaut R and the ANRS Co3 Aquitaine Cohort. Change in T lymphocytes count
after HAART initiation in HIV-infected patients with history of Mycobacterium avium complex
infection. Antiviral Therapy, 2006, 11:343-350.
06-06 Thiébaut R, Guedj J, Jacqmin-Gadda H, Chêne G, Trimoulet P, Neau D, Commenges D.
Estimation of dynamical model parameters taking into account undetectable marker values. BMC
Medical Research Methodology 2006, 6:38 (1Aug2006)
06-07 Duvignac J, Thiébaut R. CD4 natural history and informative censoring in sub-saharan
Africa. Journal of Acquired Immune Deficiency Syndrome, 2006, 43:380-381.
06-08 De la Roche, Thiébaut R, Dauman R. Behavioral audiometry: validity of audiometric
measurements obtained using the “Delaroche protocol” in babies aged 4 to 18 months suffering
from bilateral sensorineural hearing loss. International Journal of Pediatric Otorhinolaryngology,
2006, 70:993-1002
2007
07-01 Guisset O, Dilhuidy MS, Thiébaut R, Lefèvre J, Camou F, Moreau JF, Gabinski C, Blanco P.
Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care
Medicine, 2007, 33:148-152.
07-02 SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group; Thiébaut
R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital
toxoplasmosis: a meta-analysis of individual patients' data. Lancet, 2007, 369:115-22.
07-03 Pellegrin I, Breilh D, Coureau G, Boucher S, Neau D, Merel P, Lacoste D, Fleury H, Saux
MC, Pellegrin JL, Lazaro E, Dabis F, Thiébaut R. Interpretation of genotype and pharmacokinetics
for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Antimicrobial Agents Chemotherapy, 2007, 51:1473-1480.
06/09/07 12/19

07-04 Le Moing V, Thiébaut R, Chene G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaied F,
Leport C, Raffi F; the ANRS CO8 (APROCO/COPILOTE) Study Group. Long-term evolution of
CD4 count in patients with a plasma HIV RNA persistently

Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5
years after initiation of HAART: collaborative analysis of prospective studies. AIDS, 2007,
21:1185-1197.
07-13 Peuchant O, Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, Thiébaut R, Fleury H,
Masquelier B and the ANRS CO3 Aquitaine Cohort. Primary Resistance to Enfuvirtide in Recently
Infected, Antiretroviral-Naive Patients from the ANRS Aquitaine Cohort. Antiviral therapy, 2007,
12: 559-562.
07-14 Bonnet F, Chêne G, Thiébaut R, Dupon M, Lawson-Ayayi S, Pellegrin J, Dabis F, Morlat P;
for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Trends and
determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-
2004. HIV Medicine, 2007, 8:547-554.
2009
08-01 Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N,
Mercie P, Morlat P, Thiébaut R, Dabis F and the Groupe d’Epidémiologie Clinique du SIDA en
Aquitaine. Reduced bone mineral density in HIV-infected patients: prevalence and associated
factors. AIDS, 2008, 22:395-402.
08-02 Garrigue I, Doussau A, Asselineau J, Bricout H, Couzi L, Rio C, Merville P, Lafon ME,
Thiébaut R. Prediction of CMV plasma load from CMV whole blood load in renal transplant
recipients. Journal of Clinical Microbiology, 2008, 46:493-8.
08-03 Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, Dabis F, Brun-
Vezinet F, Chêne G, Thiébaut R. Comparison of Viro-Immunologic Markers Evolution
between HIV-1 and HIV-2 Infected Patients in France from the ANRS CO 3 Aquitaine and
CO 5 HIV-2 cohorts. AIDS, 2008, 22:457-468.
08-04 Duvignac J, Anglaret X, Kpozehouen A, Inwoley A, Toure S, Seyler C, Messou E, Gabillard
D, Thiébaut R. Factors associated with CD4+ T-lymphocytes decrease in sub-Saharan African HIV-
infected HAART-naïve adults: a six-year cohort study in Abidjan. HIV clinical trials, 2008, 9:26-
35.
06/09/07 14/19

08-05 Dzwonek AB, Neth OW, Thiébaut R, Gulczynska E, Chilton M, Hellwig T, Bajaj-Elliott M,
Hawdon J, Klein NJ. The role of Mannose-binding Lectin in Susceptibility to Infection in Preterm
Neonates. Pediatric research, 2008, 63:680-685.
08-06 Richert L, Bouteloup V, Thiébaut R, Chêne G. Methodological issues of non-inferiority trials
in HIV-infected patients: a need for consensus? AIDS, 2008, 22:996-7.
08-07 Pellegrin I, Wittkop L, Morand Joubert L, Neau D, Bollens D, Merel P, Lacoste D, Girard
PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D. Impact of Genotype and
Pharmacokinetics for Resistance to Darunavir/ritonavir-Based Regimens in a cohort of
Antiretroviral-Experienced Patients (PREDIZISTA Study). Antiviral Therapy, 2008, 13:271-9.
08-08 Badiou S, Thiébaut R, Aurillac-Lavignolle V, Dabis F, Laporte F, Cristol JP, Mercié P;
Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). Association of non-HDL
cholesterol with subclinical atherosclerosis in HIV-positive patients. Journal of Infection, 2008,
57:47-54.
08-09 Jacobsen MC, Thiébaut R, Fisher C, Sefe D, Clapson M, Klein N, Baxendale HE. Paediatric
HIV infection selectively and irreversibly depletes marginal zone memory B cells. The Journal of
Infectious Diseases, 2008 198:481-485.
08-10 Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F,
Fleury H, Masquelier B and the ANRS CO3 Aquitaine Cohort. Transmission of HIV-1 minority
resistant variants and response to first-line antiretroviral therapy. AIDS, 2008, 22: 1417-1423.
08-11 Thiébaut R, Walker S. When it is better to estimate a slope with only one point. QJM: An
International Journal of Medicine, 2008, 101:821-824.
08-12 M Bruyand, M-C Receveur, T Pistone, C-H Verdière, Thiébaut R, D Teuwen, D Malvy
Vaccination contre la fièvre jaune en dehors des sujets immunocompétents Yellow fever
vaccination in non-immunocompetent patients. Médecine et Maladies Infectieuses, 2008, 38:524-
532
06/09/07 15/19

08-13 Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiébaut R, Leroy V, Blanche
S, Dabis F, Abrams EJ. Antiretroviral therapy in pregnant women with advanced HIV disease and
pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS, 2008, 22: 1815-20.
08-14 Wittkop L, Commenges D, Pellegrin I, Breilh D, Neau D, Lacoste D, Pellegrin JL, Chêne G,
Dabis F, Thiébaut R. Comparison of principal component analysis, partial least square and usual
genotypic score to determine the impact of protease gene mutation on virological response upon
HAART. BMC Methods in Medical Research, 2008;8:68.
08-15 Couzi L, Thiébaut R, Carron JC, Moreau JF, Merville P, Taupin JL. Immunological
Monitoring of Calcineurin Inhibitors For Predicting Overimmunosuppression in Kidney Transplant
Recipients. Transplantation, 2008, 86:1060-1067.
2009
09-1 Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Pradier C, Thiébaut R, Law M,
Rickenback M, Stephane DW, Lundgren JD, Møller NF. Presence of the metabolic syndrome (MS)
is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-
infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study).
Diabetes Care, 2009, 32:474-480.
09-2 Pédrono G, Thiébaut R, Alioum A, Lesprit P, Fritzell B, Lévy Y, Chêne G. A new endpoint
definition improved clinical relevance and statistical power in a vaccine trial. Journal of Clinical
Epidemiology. 2009 Mar 10. [Epub ahead of print]
09-3 Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM,
Rouzioux C, Avettand-Fénoêl V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M,
Delfraissy JF. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. The
Journal of Clinical Investigation. 2009, 119:997-1007.
09-4 Chêne G, Thiébaut R. Options for clinical trials of pre and post-natal treatments for congenital
toxoplasmosis. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 104(2): 000-000, March 2009
09-5 Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux
MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.
06/09/07 16/19

Virological and immunological response in HIV-1-infected patients with multiple treatment failures
receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of
Antimicrobial Chemotherapy. 2009 ;63:1251-5.
09-6 Neth OW, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuk F, Lioznov M, Waschke
O, Fehse B, Thiébaut R, Haston RM, Klein N, Zander AR.. Influence of mannose-binding lectin
genotypes and serostatus in Allo-SCT: analysis of 131 recipients and donors. Bone Marrow
Transplantation. 2009 May 11.
09-7 Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins
M, Walker S, Porter K, Sabin C, Chêne G; on behalf of the CASCADE Collaboration. Non-AIDS-
defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009,
23:1743-53.
09-08 Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A,
Thiébaut R, Dabis F, Fleury H, Masquelier B; the ANRS CO3 Aquitaine Cohort. HIV type-1
transmission dynamics in recent seroconverters: relationship with transmission of drug resistance
and viral diversity. Antiviral Therapy. 2009, 14:551-556.
09-09 Bruyand M, Thiébaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercié P, Pellegrin JL, Neau D,
Dabis F, Morlat P, Chêne G, Bonnet F; the Groupe d’Epidémiologie Clinique du SIDA en
Aquitaine (GECSA). Role of Uncontrolled HIV RNA Level and Immunodeficiency in the
Occurrence of Malignancy in HIV-Infected Patients during the Combination Antiretroviral Therapy
Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious
Diseases. 2009, 49:1109-16.
09-10 Bains I, Thiébaut R, Callard R, Yates A. Quantifying Thymic Export: combining models of
naive T cell proliferation and TREC dynamics gives an explicit measure of thymic output. Journal
of Immunology. 2009, 183:4329-36.
09-11 Gao S, Thiébaut R. Mixed-effect models for truncated longitudinal outcomes with
nonignorable missing data. Journal of Data Science. 2009, 7:13-25.
09-12 Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC,
Thiébaut R, Chêne G, Neau D. Ribavirin plasma concentration predicts sustained virological
06/09/07 17/19

esponse to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Journal of Acquired Immune Deficiency Syndromes. 2009, 52:428-30
09-13 Brauner CM, Jolly D, Lorenzi L, Thiébaut R. Heterogeneous Viral Environment in a HIV
Spatial Model. arXiv:0905.2023v1 [math.DS] available at http://arxiv.org/abs/0905.2023
2010
10-01 Drylewicz J, Commenges D, Thiébaut R. Score Tests for Exploring Complex Models:
Application to HIV Dynamics Models. Biometrical Journal. 2009, 52:10-21
10-02 Reigadas S, Andréola ML, Wittkop L, Cosnefroy O, Anies G, Recordon-Pinson P, Thiébaut
R, Masquelier B, Fleury H. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in
raltegravir-treated patients and in in vitro infected cells. Journal of Antimicrobial Chemotherapy.
2010 Jan 5. [Epub ahead of print]
10-03 Pambrun E, Bouteloup V, Thiébaut R, Asselineau J, de Lédinghen V, Perez P; Steering
Committee of the Transient Elastography Individual Patient Data meta-analysis Study (TE IPD
Study). On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate
patients too. Journal of Clinical Epidemiology, 2010;63:342-343.
10-04 Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker
A, Thiébaut R; NEAT-WP4. Methodological issues in the use of composite endpoints in clinical
trials: examples from the HIV field. Clinical Trials, 2010;7:19-35.
10-05 Guedj J, Thiébaut R, Commenges D. Joint Modeling of the Clinical Progression and of the
Biomarkers' Dynamics Using a Mechanistic Model. Biometrics. 2010 Apr 6
10-06 Drylewicz J, Eholie S, Maiga M, Zannou DM, Sow PS, Ekouevi DK, Peterson K, Bissagnene
E, Dabis F, Thiébaut R; International epidemiologic Databases to Evaluate AIDS (IeDEA) West
Africa Collaboration. First-year lymphocyte T CD4+ response to antiretroviral therapy according to
the HIV type in the IeDEA West Africa collaboration. AIDS, 2010 ;24:1043-1050.
10-07 Friis-Møller N, Thiébaut R, Reiss P, Weber R, D’Arminio Monforte A, De Wit S, El-Sadr
W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD and Law M for the D:A:D study
06/09/07 18/19

group. Predicting the risk of cardiovascular disease in HIV-infected patients; The Data-collection
on Adverse Effects of Anti-HIV Drugs (D:A:D) Study. European Journal of Cardiovascular
Prevention and Rehabilitation. 2010, 17:491-501.
10-08 Commenges D, Jolly D, Drylewicz J, Putter H, Thiébaut R. Inference in HIV dynamics
models via hierarchical likelihood. Computational Statistics & Data Analysis, 2010; 55:446-456.
10-09 Achhra AC, Zhou J, Dabis F, Pujari S, Thiébaut R, Law M, Bonnet F. Difference in Absolute
CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. J
AIDS Clinic Res, 2010, 1:101.
10-10 Lewden C, Thiébaut R, Boufassa F, Coulibaly A, Malateste K, Seng R, Toni TD, Inwoley A,
Rouzioux C, Minga A, Anglaret X, Meyer L. Comparison of Early CD4 T-Cell Count in HIV-1
Seroconverters in Côte d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts. Journal
of Acquired Immune Deficiency Syndromes. 2010, 53:260-265.
10-11 Déti E, Thiébaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, Pellegrin J, Malvy D,
Tchamgoué S, Dabis F, Morlat P; for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine
(GECSA). Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS
C03 Aquitaine Cohort, France. HIV Medicine, 2010, 11:308-317.
06/09/07 19/19